Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity.
Goodell V, Disis ML. Goodell V, et al. J Immunol Methods. 2005 Apr;299(1-2):129-38. doi: 10.1016/j.jim.2005.02.002. Epub 2005 Mar 18. J Immunol Methods. 2005. PMID: 15914197
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, Li CI, Prentice R, Hanash SM, Disis ML. Lu H, et al. Among authors: goodell v. Cancer Prev Res (Phila). 2012 Aug;5(8):1036-43. doi: 10.1158/1940-6207.CAPR-11-0558. Epub 2012 Jun 19. Cancer Prev Res (Phila). 2012. PMID: 22715141 Free PMC article.
Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer.
Lu H, Goodell V, Disis ML. Lu H, et al. Among authors: goodell v. Expert Opin Ther Targets. 2007 Feb;11(2):235-44. doi: 10.1517/14728222.11.2.235. Expert Opin Ther Targets. 2007. PMID: 17227237 Review.
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
Coveler AL, Goodell V, Webster DJ, Salazar LG, Fintak PA, Childs JS, Higgins DM, Disis ML. Coveler AL, et al. Among authors: goodell v. Breast Cancer Res Treat. 2009 Jan;113(1):95-100. doi: 10.1007/s10549-008-9910-y. Epub 2008 Jan 31. Breast Cancer Res Treat. 2009. PMID: 18236151
His-tag ELISA for the detection of humoral tumor-specific immunity.
Goodell V, McNeel D, Disis ML. Goodell V, et al. BMC Immunol. 2008 May 29;9:23. doi: 10.1186/1471-2172-9-23. BMC Immunol. 2008. PMID: 18510754 Free PMC article.
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.
Goodell V, Waisman J, Salazar LG, de la Rosa C, Link J, Coveler AL, Childs JS, Fintak PA, Higgins DM, Disis ML. Goodell V, et al. Mol Cancer Ther. 2008 Mar;7(3):449-54. doi: 10.1158/1535-7163.MCT-07-0386. Epub 2008 Mar 4. Mol Cancer Ther. 2008. PMID: 18319334
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer.
Lu H, Goodell V, Disis ML. Lu H, et al. Among authors: goodell v. J Proteome Res. 2008 Apr;7(4):1388-94. doi: 10.1021/pr700818f. Epub 2008 Feb 27. J Proteome Res. 2008. PMID: 18311901 Review.
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
Salazar LG, Coveler AL, Swensen RE, Gooley TA, Goodell V, Schiffman K, Disis ML. Salazar LG, et al. Among authors: goodell v. Clin Immunol. 2007 Dec;125(3):275-80. doi: 10.1016/j.clim.2007.08.006. Epub 2007 Oct 29. Clin Immunol. 2007. PMID: 17913588 Clinical Trial.
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML. Dang Y, et al. Among authors: goodell v. Clin Cancer Res. 2007 Mar 15;13(6):1883-91. doi: 10.1158/1078-0432.CCR-06-2083. Clin Cancer Res. 2007. PMID: 17363545
Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.
Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Montgomery RB, et al. Among authors: goodell v. Cancer Res. 2005 Jan 15;65(2):650-6. Cancer Res. 2005. PMID: 15695410
24 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback